[The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
Rapid growth of dementia patients prompts improvement of medical and care systems. For this reason, biological markers for Alzheimer's disease are necessary, which enable us detect Alzheimer's disease before onset of dementia and evaluate drug effects on evidence based procedure. Here, we summarized the developing field of biological markers and reported recent results of large-scale multicenter study of CSF tau and A beta for clinical practice.
Shoji
M
M
Department of Neurology, Gunma University, School of Medicine.
D000544:Alzheimer Disease / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic; D005819:Genetic Markers; D006801:Humans; D015337:Multicenter Studies as Topic; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D012680:Sensitivity and Specificity; D016875:tau Proteins / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D015415:Biomarkers; D005819:Genetic Markers; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C092862:amyloid beta-protein (10-43); D016875:tau Proteins